L’ACMTS tient à appuyer les décideurs du secteur de la santé canadiens durant cette période difficile et incertaine.
Pour trouver des outils, ressources et données probantes touchant la COVID-19, consultez notre portail sur la COVID-19.


Begin main content

Formulaire de demande

1. Information About the Applicant

2. Product Description

3. Stage of Development

To be eligible for CADTH Scientific Advice, a drug product must be in early stage development at a point where changes in development plans based on Scientific Advice are still possible.

4. Purpose of Application

5. Proposed Scientific Advice Meeting

A Scientific Advice staff member will contact you to discuss potential meeting dates. 

6. Briefing Book Content

See Type of Advice Offered by CADTH Scientific Advice for common topics on which advice may be sought.

7. Questions for CADTH Scientific Advice Staff

8. Declaration for the CADTH Scientific Advice Program

Application to the CADTH Scientific Advice Program constitutes an agreement with the Program policies, guidelines and processes as described on the CADTH Scientific Advice website. The applicant has read, understood and hereby accepts the following:

9. Permission to Share Information with Patient Representatives

Patient involvement is part of the CADTH Scientific Advice process for every application; however, confidential information from the applicant will be shared with patient representative(s) only with permission of the applicant, as provided below.

Name and title of person providing authorized consent on behalf of the applicant. Providing your name here indicates that you have authority to bind the applicant.